Eric Diffenderfer

Dr. Eric Diffenderfer

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
AVAnastasia Velalopoulou
Anastasia Velalopoulou
IKIlias V. Karagounis
Ilias V. Karagounis
GCGwendolyn M. Cramer
Gwendolyn M. Cramer
MKMichele Kim
Michele Kim
GSGiorgos Skoufos
Giorgos Skoufos
Theresa M. BuschTheresa M. Busch
Theresa M. Busch
In studies of electron and proton radiotherapy, ultrahigh dose rates of FLASH radiotherapy appear to produce fewer toxicities than standard dose rates while maintaining local tumor control. FLASH-proton radiotherapy (F-PRT) brings the spatial advantages of PRT to FLASH dose rates (>40 Gy/second), making it important to understand if and how F-PRT spares normal tissues while providing antitumor efficacy that is equivalent to standard-proton radiotherapy (S-PRT). Here we studied PRT damage to skin and mesenchymal tissues of muscle and bone and found that F-PRT of the C57BL/6 murine hind leg produced fewer severe toxicities leading to death or requiring euthanasia than S-PRT of the same dose. RNA-seq analyses of murine skin and bone revealed pathways upregulated by S-PRT yet unaltered by F-PRT, such as apoptosis signaling and keratinocyte differentiation in skin, as well as osteoclast differentiation and chondrocyte development in bone. Corroborating these findings, F-PRT reduced skin injury, stem cell depletion, and inflammation, mitigated late effects including lymphedema, and decreased histopathologically detected myofiber atrophy, bone resorption, hair follicle atrophy, and epidermal hyperplasia. F-PRT was equipotent to S-PRT in control of two murine sarcoma models, including at an orthotopic intramuscular site, thereby establishing its relevance to mesenchymal cancers. Finally, S-PRT produced greater increases in TGFβ1 in murine skin and the skin of canines enrolled in a phase I study of F-PRT versus S-PRT. Collectively, these data provide novel insights into F-PRT-mediated tissue sparing and support its ongoing investigation in applications that would benefit from this sparing of skin and mesenchymal tissues.Significance: These findings will spur investigation of FLASH radiotherapy in sarcoma and additional cancers where mesenchymal tissues are at risk, including head and neck cancer, breast cancer, and pelvic malignancies.

23 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MKMichele Kim
Michele Kim
IVIoannis I. Verginadis
Ioannis I. Verginadis
DGDenisa Goia
Denisa Goia
AHAllison Haertter
Allison Haertter
KSKhayrullo Shoniyozov
Khayrullo Shoniyozov
EDEric Diffenderfer
Eric Diffenderfer
Ultra-high dose rate FLASH proton radiotherapy (F-PRT) has been shown to reduce normal tissue toxicity compared to standard dose rate proton radiotherapy (S-PRT) in experiments using the entrance portion of the proton depth dose profile, while proton therapy uses a spread-out Bragg peak (SOBP) with unknown effects on FLASH toxicity sparing. To investigate, the biological effects of F-PRT using an SOBP and the entrance region were compared to S-PRT in mouse intestine. In this study, 8–10-week-old C57BL/6J mice underwent 15 Gy (absorbed dose) whole abdomen irradiation in four groups: (1) SOBP F-PRT, (2) SOBP S-PRT, (3) entrance F-PRT, and (4) entrance S-PRT. Mice were injected with EdU 3.5 days after irradiation, and jejunum segments were harvested and preserved. EdU-positive proliferating cells and regenerated intestinal crypts were quantified. The SOBP had a modulation (width) of 2.5 cm from the proximal to distal 90%. Dose rates with a SOBP for F-PRT or S-PRT were 108.2 ± 8.3 Gy/s or 0.82 ± 0.14 Gy/s, respectively. In the entrance region, dose rates were 107.1 ± 15.2 Gy/s and 0.83 ± 0.19 Gy/s, respectively. Both entrance and SOBP F-PRT preserved a significantly higher number of EdU + /crypt cells and percentage of regenerated crypts compared to S-PRT. Moreover, tumor growth studies showed no difference between SOBP and entrance for either of the treatment modalities.

13 October 2021 in Medical Physics
Verified
Journal Article
Closed access
PDF file
EDEric Diffenderfer
Eric Diffenderfer
BSBrita S. Sørensen
Brita S. Sørensen
AMAlejandro Mazal
Alejandro Mazal
DCDavid J. Carlson
David J. Carlson

9 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
PCPriyanka Chowdhury
Priyanka Chowdhury
AVAnastasia Velalopoulou
Anastasia Velalopoulou
IVIoannis I. Verginadis
Ioannis I. Verginadis
GMGeorge Morcos
George Morcos
PLPhoebe E. Loo
Phoebe E. Loo
CKConstantinos Koumenis
Constantinos Koumenis
Head and neck cancer radiotherapy often damages salivary glands and oral mucosa, severely negatively impacting patients’ quality of life. The ability of FLASH proton radiotherapy (F-PRT) to decrease normal tissue toxicity while maintaining tumor control compared with standard proton radiotherapy (S-PRT) has been previously demonstrated for several tissues. However, its potential in ameliorating radiation-induced salivary gland dysfunction and oral mucositis and controlling orthotopic head and neck tumor growth has not been reported. The head and neck area of C57BL/6 mice was irradiated with a single dose of radiotherapy (ranging from 14–18 Gy) or a fractionated dose of 8 Gy × 3 of F-PRT (128 Gy/second) or S-PRT (0.95 Gy/second). Following irradiation, the mice were studied for radiation-induced xerostomia by measuring their salivary flow. Oral mucositis was analyzed by histopathologic examination. To determine the ability of F-PRT to control orthotopic head and neck tumors, tongue tumors were generated in the mice and then irradiated with either F-PRT or S-PRT. Mice treated with either a single dose or fractionated dose of F-PRT showed significantly improved survival than those irradiated with S-PRT. F-PRT–treated mice showed improvement in their salivary flow. S-PRT–irradiated mice demonstrated increased fibrosis in their tongue epithelium. F-PRT significantly increased the overall survival of the mice with orthotopic tumors compared with the S-PRT–treated mice. The demonstration that F-PRT decreases radiation-induced normal tissue toxicity without compromising tumor control, suggests that this modality could be useful for the clinical management of patients with head and neck cancer.

29 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JLJose Marcio Luna
Jose Marcio Luna
ABAndrew R. Barsky
Andrew R. Barsky
RSRussell T. Shinohara
Russell T. Shinohara
LRLeonid Roshkovan
Leonid Roshkovan
MHMichelle Hershman
Michelle Hershman
Despina KontosDespina Kontos
Despina Kontos
We evaluate radiomic phenotypes derived from CT scans as early predictors of overall survival (OS) after chemoradiation in stage III primary lung adenocarcinoma. We retrospectively analyzed 110 thoracic CT scans acquired between April 2012−October 2018. Patients received a median radiation dose of 66.6 Gy at 1.8 Gy/fraction delivered with proton (55.5%) and photon (44.5%) beam treatment, as well as concurrent chemotherapy (89%) with carboplatin-based (55.5%) and cisplatin-based (36.4%) doublets. A total of 56 death events were recorded. Using manual tumor segmentations, 107 radiomic features were extracted. Feature harmonization using ComBat was performed to mitigate image heterogeneity due to the presence or lack of intravenous contrast material and variability in CT scanner vendors. A binary radiomic phenotype to predict OS was derived through the unsupervised hierarchical clustering of the first principal components explaining 85% of the variance of the radiomic features. C-scores and likelihood ratio tests (LRT) were used to compare the performance of a baseline Cox model based on ECOG status and age, with a model integrating the radiomic phenotype with such clinical predictors. The model integrating the radiomic phenotype (C-score = 0.69, 95% CI = (0.62, 0.77)) significantly improved (p<0.005) upon the baseline model (C-score = 0.65, CI = (0.57, 0.73)). Our results suggest that harmonized radiomic phenotypes can significantly improve OS prediction in stage III NSCLC after chemoradiation.

10 April 2024 in Medical Physics
Verified
Journal Article
Open access
DCDixin Chen
Dixin Chen
SMSeyyedeh Azar Oliaei Motlagh
Seyyedeh Azar Oliaei Motlagh
FSFrançois Vander Stappen
François Vander Stappen
RLRudi Labarbe
Rudi Labarbe
BBBeryl Bell
Beryl Bell
EDEric Diffenderfer
Eric Diffenderfer
Background: Cyclotron‐based proton therapy systems utilize the highest proton energies to achieve an ultra‐high dose rate (UHDR) for FLASH radiotherapy. The deep‐penetrating range associated with this high energy can be modulated by inserting a uniform plate of proton‐stopping material, known as a range shifter, in the beam path at the nozzle to bring the Bragg peak within the target while ensuring high proton transport efficiency for UHDR. Aluminum has been recently proposed as a range shifter material mainly due to its high compactness and its mechanical properties. A possible drawback lies in the fact that aluminum has a larger cross‐section of producing secondary neutrons compared to conventional plastic range shifters. Accordingly, an increase in secondary neutron contamination was expected during the delivery of range‐modulated FLASH proton therapy, potentially heightening neutron‐induced carcinogenic risks to the patient.Purpose: We conducted neutron dosimetry using simulations and measurements to evaluate excess dose due to neutron exposure during UHDR proton irradiation with aluminum range shifters compared to plastic range shifters.Methods: Monte Carlo simulations in TOPAS were performed to investigate the secondary neutron production characteristics with aluminum range shifter during 225 MeV single‐spot proton irradiation. The computational results were validated against measurements with a pair of ionization chambers in an out‐of‐field region ( 30 cm) and with a Proton Recoil Scintillator‐Los Alamos rem meter in a far‐out‐of‐field region (0.5–2.5 m). The assessments were repeated with solid water slabs as a surrogate for the conventional range shifter material to evaluate the impact of aluminum on neutron yield. The results were compared with the International Electrotechnical Commission (IEC) standards to evaluate the clinical acceptance of the secondary neutron yield.Results: For a range modulation up to 26 cm in water, the maximum simulated and measured values of out‐of‐field secondary neutron dose equivalent per therapeutic dose with aluminum range shifter were found to be and , respectively, overall higher than the solid water cases (simulation: ; measurement: ). The maximum far out‐of‐field secondary neutron dose equivalent was found to be () and () for the simulations and rem meter measurements, respectively, also higher than the solid water counterparts (simulation: () ; measurement: () ).Conclusions: We conducted simulations and measurements of secondary neutron production under proton irradiation at FLASH energy with range shifters. We found that the secondary neutron yield increased when using aluminum range shifters compared to conventional materials while remaining well below the non‐primary radiation limit constrained by the IEC regulations.